Printer Friendly

RAYTHEON UNIT TO ENGINEER BOSTON MANUFACTURING PLANT FOR GENZYME

 RAYTHEON UNIT TO ENGINEER BOSTON MANUFACTURING PLANT FOR GENZYME
 LEXINGTON, Mass., Dec. 9 /PRNewswire/ -- Raytheon Company (NYSE: RTN) announced today that the Boston office of its United Engineers & Constructors subsidiary will provide engineering services for Genzyme Corporation's new $75 million manufacturing facility on the Allston Landing site in Boston.
 "We're very pleased," said Charles Q. Miller, president and CEO of United Engineers & Constructors, "that Genzyme has recognized the biotech engineering capabilities and experience of a local firm with this assignment. Both we and the Raytheon organization welcome the opportunity to participate in the continued development of high-tech industry in Massachusetts."
 Genzyme's new manufacturing plant will produce a recombinant form of a human enzyme called glucocerebrosidase (r-GCR). This enzyme is being developed for the treatment of patients with Gaucher disease, a rare genetic disorder which results in an insufficient production of the enzyme. The Food and Drug Administration has given Genzyme permission to initiate Phase III human clinical testing of r-GCR. r-GCR is expected to be a second generation product of the biopharmaceutical, Ceredase(R) alglucerase injection, approved by the FDA in April 1991.
 In addition, the plant will be used to manufacture Thyrogen(tm) hormone, a recombinant form of a human thyroid stimulating hormone. This protein is currently in human clinical testing as an adjunct therapy in the diagnosis and treatment of thyroid cancer.
 Genzyme Corporation is an international, diversified human healthcare products company based in Cambridge, Mass. Genzyme has the resources and capabilities to research, develop, manufacture, and sell healthcare products and services on an international basis. The company operates facilities in the United States, England, Japan, and The Netherlands. Since its founding in 1981, the company has developed a strategic market position through its product sales in three key areas: Biotherapeutics, Diagnostic Products and Services, and Pharmaceuticals and Fine Chemicals.
 Raytheon, headquartered in Lexington, Mass., is active in electronics, aviation, appliances, energy and environmental services, engineering and construction, and publishing. The company recorded sales of $9.3 billion in 1990.
 -0- 12/9/91
 /CONTACT: Ed Powers of Raytheon, 617-860-2415/
 (RTN) CO: Raytheon Company; Genzyme Corporation ST: Massachusetts IN: ARO SU:


DD -- NE017 -- 0699 12/09/91 16:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 9, 1991
Words:362
Previous Article:COORS BREWING CO. ANNOUNCES THIRD NEW EXPORT MARKET IN 1991 WITH EXPANSION TO CAYMAN ISLANDS
Next Article:THE PRUDENTIAL FLORIDA REALTY REPORTS 10 PERCENT SALES INCREASE THROUGH OCTOBER
Topics:


Related Articles
RAYTHEON UNIT WINS CONTRACT TO DECOMMISSION LONG ISLAND NUCLEAR STATION
RAYTHEON UNIT WINS AWARD FOR KOREAN LUBE OIL PLANT
RAYTHEON UNIT WINS CONTRACT FOR ETHYLBENZENE/STYRENE PLANT IN CHINA
RAYTHEON UNIT WINS $48 MILLION CONTRACT FOR COGENERATION PLANT PROJECT
RAYTHEON UNIT COMPLETES WORLD'S LARGEST ALTERNATIVE REFRIGERANT PLANT FOR ICI
RAYTHEON UNIT WINS ETHYLBENZENE/STYRENE CONTRACT IN CHINA
RAYTHEON UNIT WINS CONTRACT FOR POWER PROJECT IN MARYLAND
RAYTHEON UNIT BUILDS ENVIRONMENTAL FACILITIES FOR SMITHKLINE BEECHAM IN THE U.K.
RAYTHEON ENGINEERS & CONSTRUCTORS WINS $364 MILLION CONTRACT FOR ACME STEEL PLANT MODERNIZATION PROJECT
RAYTHEON ENGINEERS & CONSTRUCTORS AWARDED CHEMICAL FERTILIZER PROJECT IN CHINA

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters